The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases

Overview

Journal Invest Ophthalmol Vis Sci

Date 2025 Jan 21

PMID 39836404

Authors

Joseph B Lin

Rajendra S Apte

Affiliations

Soon will be listed here.

Abstract

Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.

References

Heier J, Lad E, Holz F, Rosenfeld P, Guymer R, Boyer D . Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023; 402(10411):1434-1448. DOI: 10.1016/S0140-6736(23)01520-9. View

Zhou T, Hu Y, Chen Y, Zhou K, Zhang B, Gao G . The pathogenic role of the canonical Wnt pathway in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009; 51(9):4371-9. PMC: 2941176. DOI: 10.1167/iovs.09-4278. View

Cherepanoff S, McMenamin P, Gillies M, Kettle E, Sarks S . Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2009; 94(7):918-25. DOI: 10.1136/bjo.2009.165563. View

Maller J, Fagerness J, Reynolds R, Neale B, Daly M, Seddon J . Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007; 39(10):1200-1. DOI: 10.1038/ng2131. View

Nakamura R, Sene A, Santeford A, Gdoura A, Kubota S, Zapata N . IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun. 2015; 6:7847. PMC: 4918330. DOI: 10.1038/ncomms8847. View

Seddon J, Yu Y, Miller E, Reynolds R, Tan P, Gowrisankar S . Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet. 2013; 45(11):1366-70. PMC: 3902040. DOI: 10.1038/ng.2741. View

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

Bhisitkul R, Desai S, Boyer D, Sadda S, Zhang K . Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology. 2016; 123(6):1269-77. DOI: 10.1016/j.ophtha.2016.01.033. View

Haines J, Hauser M, Schmidt S, Scott W, Olson L, Gallins P . Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005; 308(5720):419-21. DOI: 10.1126/science.1110359. View

10.

Li D, Xie K, Ding G, Li J, Chen K, Li H . Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2013; 346(1):45-52. DOI: 10.1016/j.canlet.2013.12.004. View

11.

Lanzetta P, Korobelnik J, Heier J, Leal S, Holz F, Clark W . Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024; 403(10432):1141-1152. DOI: 10.1016/S0140-6736(24)00063-1. View

12.

Terao R, Sohn B, Yamamoto T, Lee T, Colasanti J, Pfeifer C . Cholesterol Accumulation Promotes Photoreceptor Senescence and Retinal Degeneration. Invest Ophthalmol Vis Sci. 2024; 65(10):29. PMC: 11343002. DOI: 10.1167/iovs.65.10.29. View

13.

Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C . Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308(5720):385-9. PMC: 1512523. DOI: 10.1126/science.1109557. View

14.

Lin J, Sene A, Wiley L, Santeford A, Nudleman E, Nakamura R . WNT7A/B promote choroidal neovascularization. Exp Eye Res. 2018; 174:107-112. PMC: 6110966. DOI: 10.1016/j.exer.2018.05.033. View

15.

Oladipupo S, Smith C, Santeford A, Park C, Sene A, Wiley L . Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A. 2014; 111(37):13379-84. PMC: 4169958. DOI: 10.1073/pnas.1324235111. View

16.

Zhang C, Han M, Wu S . Silencing fibroblast growth factor 7 inhibits krypton laser-induced choroidal neovascularization in a rat model. J Cell Biochem. 2019; 120(8):13792-13801. DOI: 10.1002/jcb.28652. View

17.

Toomey C, Kelly U, Saban D, Bowes Rickman C . Regulation of age-related macular degeneration-like pathology by complement factor H. Proc Natl Acad Sci U S A. 2015; 112(23):E3040-9. PMC: 4466717. DOI: 10.1073/pnas.1424391112. View

18.

Khanani A, Kotecha A, Chang A, Chen S, Chen Y, Guymer R . TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024; 131(8):914-926. DOI: 10.1016/j.ophtha.2024.02.014. View

19.

Droho S, Rajesh A, Cuda C, Perlman H, Lavine J . CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization. JCI Insight. 2023; 8(7). PMC: 10132149. DOI: 10.1172/jci.insight.168142. View

20.

Sene A, Chin-Yee D, Apte R . Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med. 2014; 21(1):43-51. PMC: 4282831. DOI: 10.1016/j.molmed.2014.10.005. View